Survodutide Dosing Protocol: 10 mg Vial — Week-by-Week Titration & Supplies
给药方案详解
以下方案内容整理自公开资料与临床文献，仅供研究参考，不构成医疗建议。
Quickstart highlights
Survodutide (BI 456906, Boehringer Ingelheim) is a once-weekly dual GLP-1/glucagon receptor agonist.
- Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
- At 5 mg/mL: 0.3 mg = 6 units, 0.9 mg = 18 units, 1.8 mg = 36 units, 3.6 mg = 72 units.
- OASIS Phase 2b trial: 3.6 mg dose achieved 14.9% body weight reduction at 46 weeks.
- One 10 mg vial provides approximately 2.8 maintenance doses at 3.6 mg/week.
- Monitor liver enzymes monthly — glucagon agonism can transiently elevate ALT/AST.
Dosing table
For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.
| Week | Dose (µg) | Units | Frequency | Notes |
|---|---|---|---|---|
| 1-4 | 300 | 6 | Once weekly | 0.3 mg starting dose — 6 units; assess GI tolerability before advancing |
| 5-8 | 900 | 18 | Once weekly | 0.9 mg — 18 units; step-3x increase typical of dual agonist titration |
| 9-12 | 1800 | 36 | Once weekly | 1.8 mg — 36 units; mid-dose assessment |
| 13-16 | 3600 | 72 | Once weekly | 3.6 mg maintenance — 72 units; highest dose from Phase 2b OASIS trial |
Gradual approach
| Week | Dose (µg) | Units | Notes |
|---|---|---|---|
| 1-8 | 300 | 6 | Extend 0.3 mg phase to 8 weeks for sensitive patients |
| 9-16 | 900 | 18 | 0.9 mg for 8 weeks before advancing to 1.8 mg |
Your free Survodutide tracker
- Dose reminders
- Injection logging
- Cycle progress
Reconstitution steps
- Draw 2 mL bacteriostatic water into a 3 mL syringe; inject slowly down the vial wall.
- Swirl gently until lyophilized powder dissolves completely; do not shake.
- Final concentration: 5 mg/mL (10 mg / 2 mL). At 5 mg/mL: 1 unit = 50 µg.
- Label with date and concentration; refrigerate at 2–8 °C immediately. Use within 28 days.
Supplies needed
8-week plan
- 1 vial
- 8 syringes
- 2 mL bac water
- 8 alcohol swabs
16-week plan
- 1 vial
- 16 syringes
- 2 mL bac water
- 16 alcohol swabs
Protocol overview & cycle notes
Support weight loss and hepatic fat reduction through dual GLP-1/glucagon receptor agonism, titrating survodutide from 0.3 mg to 3.6 mg over 12 weeks per Phase 2b OASIS trial protocol.
Cycle length: 16 weeks on.
Off-cycle: 8 weeks off between cycles; monitor liver enzymes and body weight during off-cycle.
Storage & handling
Injection & tracking tips
- Rotate injection sites weekly (abdomen, outer thigh, upper arm).
- Hepatic side effects: survodutide's glucagon agonism increases liver enzyme activity — monitor ALT/AST monthly at doses ≥1.8 mg.
- Inject at a consistent weekly time; survodutide's once-weekly design allows ±24-hour flexibility.
Tracking
Logging helps you and your provider spot patterns and adjust dose or timing.
- Log body weight weekly; expect accelerated weight loss at 1.8–3.6 mg doses.
- Record ALT/AST labs monthly — glucagon component may transiently elevate liver enzymes.
- Track stool consistency and frequency; diarrhea is most common at dose increases.
How this works & references
Sources
- Source: OASIS Phase 2b (NCT04667377) — Survodutide 3.6 mg: 14.9% weight loss at 46 weeks
- Survodutide MASH Phase 3 trials (NCT05656651) — ongoing
Frequently asked questions
What distinguishes survodutide from semaglutide for weight loss?
Is survodutide FDA-approved?
Why does survodutide titrate in such large steps (0.3 to 0.9 mg)?
Can survodutide help with fatty liver disease?
How many vials do I need for a 16-week cycle?
Related protocols
KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide
KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.
View protocolGLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide
GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.
View protocolVilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide
Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.
View protocolVesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide
Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.
View protocolThis content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.
Quickstart highlights
Survodutide (BI 456906, Boehringer Ingelheim) is a once-weekly dual GLP-1/glucagon receptor agonist.
- Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
- At 5 mg/mL: 0.3 mg = 6 units, 0.9 mg = 18 units, 1.8 mg = 36 units, 3.6 mg = 72 units.
- OASIS Phase 2b trial: 3.6 mg dose achieved 14.9% body weight reduction at 46 weeks.
- One 10 mg vial provides approximately 2.8 maintenance doses at 3.6 mg/week.
- Monitor liver enzymes monthly — glucagon agonism can transiently elevate ALT/AST.
Dosing table
For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.
| Week | Dose (µg) | Units | Frequency | Notes |
|---|---|---|---|---|
| 1-4 | 300 | 6 | Once weekly | 0.3 mg starting dose — 6 units; assess GI tolerability before advancing |
| 5-8 | 900 | 18 | Once weekly | 0.9 mg — 18 units; step-3x increase typical of dual agonist titration |
| 9-12 | 1800 | 36 | Once weekly | 1.8 mg — 36 units; mid-dose assessment |
| 13-16 | 3600 | 72 | Once weekly | 3.6 mg maintenance — 72 units; highest dose from Phase 2b OASIS trial |
Gradual approach
| Week | Dose (µg) | Units | Notes |
|---|---|---|---|
| 1-8 | 300 | 6 | Extend 0.3 mg phase to 8 weeks for sensitive patients |
| 9-16 | 900 | 18 | 0.9 mg for 8 weeks before advancing to 1.8 mg |
Your free Survodutide tracker
- Dose reminders
- Injection logging
- Cycle progress
Reconstitution steps
- Draw 2 mL bacteriostatic water into a 3 mL syringe; inject slowly down the vial wall.
- Swirl gently until lyophilized powder dissolves completely; do not shake.
- Final concentration: 5 mg/mL (10 mg / 2 mL). At 5 mg/mL: 1 unit = 50 µg.
- Label with date and concentration; refrigerate at 2–8 °C immediately. Use within 28 days.
Supplies needed
8-week plan
- 1 vial
- 8 syringes
- 2 mL bac water
- 8 alcohol swabs
16-week plan
- 1 vial
- 16 syringes
- 2 mL bac water
- 16 alcohol swabs
Protocol overview & cycle notes
Support weight loss and hepatic fat reduction through dual GLP-1/glucagon receptor agonism, titrating survodutide from 0.3 mg to 3.6 mg over 12 weeks per Phase 2b OASIS trial protocol.
Cycle length: 16 weeks on.
Off-cycle: 8 weeks off between cycles; monitor liver enzymes and body weight during off-cycle.
Storage & handling
Injection & tracking tips
- Rotate injection sites weekly (abdomen, outer thigh, upper arm).
- Hepatic side effects: survodutide's glucagon agonism increases liver enzyme activity — monitor ALT/AST monthly at doses ≥1.8 mg.
- Inject at a consistent weekly time; survodutide's once-weekly design allows ±24-hour flexibility.
Tracking
Logging helps you and your provider spot patterns and adjust dose or timing.
- Log body weight weekly; expect accelerated weight loss at 1.8–3.6 mg doses.
- Record ALT/AST labs monthly — glucagon component may transiently elevate liver enzymes.
- Track stool consistency and frequency; diarrhea is most common at dose increases.
How this works & references
Sources
- Source: OASIS Phase 2b (NCT04667377) — Survodutide 3.6 mg: 14.9% weight loss at 46 weeks
- Survodutide MASH Phase 3 trials (NCT05656651) — ongoing
Frequently asked questions
What distinguishes survodutide from semaglutide for weight loss?
Is survodutide FDA-approved?
Why does survodutide titrate in such large steps (0.3 to 0.9 mg)?
Can survodutide help with fatty liver disease?
How many vials do I need for a 16-week cycle?
Related protocols
KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide
KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.
View protocol
GLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide
GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.
View protocol
Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide
Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.
View protocol
Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide
Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.
View protocol
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.